Export markets

Our goal is to provide high quality and at the same time affordable medicines to the largest number of patients around the world.

In 2017, the export department was established in the company. Just in a few years of intense work Solopharm entered CIS countries markets and the developing regions of Southeast Asia and Central Africa. In each country our company successfully cooperates with distribution companies and constantly expands available range of drugs and medical products. The well-coordinated work of our team and our local partners allows to respond quickly to the patient’s needs in medicines, including essential ones.

The high quality of products and their compliance with international standards are TOP priorities for our company. All drugs and medical products manufactured by Solopharm comply with GMP and ISO 13485 standards, that is confirmed by official certificates. The high quality of medicines is confirmed not only by official certificates, but also by the choice of millions of people around the world.

In 2026, Solopharm is launching a new chapter in its global expansion, elevating its international presence to an entirely new level. Leveraging a robust portfolio, the company is strategically focused on entering the world’s most promising and dynamic markets.

Our immediate expansion priorities include Brazil, Chile, Mexico, Colombia, the UAE, Saudi Arabia, Turkmenistan, and Malaysia. These countries will serve as strategic gateways, enabling broader access across Latin America, the Middle East, and Southeast Asia.

This expansion will significantly strengthen Solopharm’s global footprint while providing millions of new patients with access to modern and essential medicines — reinforcing our role as a trusted partner in global healthcare.